These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 36052089)
1. Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression. Gomes YCP; Freitas NL; Souza FS; Sandim V; Pereira DA; Nogueira FCS; Echevarria-Lima J; Leite ACCB; Lima MASD; Silva MTT; Araújo AQC; Vicente ACP; Espíndola OM Front Immunol; 2022; 13():949516. PubMed ID: 36052089 [TBL] [Abstract][Full Text] [Related]
2. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression. Souza FDS; Freitas NL; Gomes YCP; Torres RC; Echevarria-Lima J; da Silva-Filho IL; Leite ACCB; de Lima MASD; da Silva MTT; Araújo AQC; Espíndola OM Front Immunol; 2021; 12():737941. PubMed ID: 34764955 [TBL] [Abstract][Full Text] [Related]
3. Lessons from the Cerebrospinal Fluid Analysis of HTLV-1-Infected Individuals: Biomarkers of Inflammation for HAM/TSP Development. Freitas NL; Gomes YCP; Souza FDS; Torres RC; Echevarria-Lima J; Leite ACCB; Lima MASD; Araújo AQC; Silva MTT; Espíndola OM Viruses; 2022 Sep; 14(10):. PubMed ID: 36298702 [TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon. Takatani M; Crispim ME; Fraiji N; Stefani MM; Kiesslich D Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e5. PubMed ID: 28380116 [TBL] [Abstract][Full Text] [Related]
5. An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. Yamauchi J; Araya N; Yagishita N; Sato T; Yamano Y Pharmacol Ther; 2021 Feb; 218():107669. PubMed ID: 32835825 [TBL] [Abstract][Full Text] [Related]
6. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Sato T; Yagishita N; Tamaki K; Inoue E; Hasegawa D; Nagasaka M; Suzuki H; Araya N; Coler-Reilly A; Hasegawa Y; Tsuboi Y; Takata A; Yamano Y Front Microbiol; 2018; 9():1651. PubMed ID: 30090093 [TBL] [Abstract][Full Text] [Related]
7. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. Sato T; Coler-Reilly A; Utsunomiya A; Araya N; Yagishita N; Ando H; Yamauchi J; Inoue E; Ueno T; Hasegawa Y; Nishioka K; Nakajima T; Jacobson S; Izumo S; Yamano Y PLoS Negl Trop Dis; 2013; 7(10):e2479. PubMed ID: 24130912 [TBL] [Abstract][Full Text] [Related]
8. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Guerreiro JB; Santos SB; Morgan DJ; Porto AF; Muniz AL; Ho JL; Teixeira AL; Teixeira MM; Carvalho EM Clin Exp Immunol; 2006 Aug; 145(2):296-301. PubMed ID: 16879249 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Saito M; Tanaka R; Arishima S; Matsuzaki T; Ishihara S; Tokashiki T; Ohya Y; Takashima H; Umehara F; Izumo S; Tanaka Y Retrovirology; 2013 May; 10():51. PubMed ID: 23651542 [TBL] [Abstract][Full Text] [Related]
11. Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study. de Oliveira CJV; Neto JAC; Liberato de Matos SNF; Oliveira P; Tannus M; Castro N; Rocha PN; Carvalho EM J Sex Med; 2023 Feb; 20(3):269-276. PubMed ID: 36751985 [TBL] [Abstract][Full Text] [Related]
12. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression. Matsuura E; Nozuma S; Tashiro Y; Kubota R; Izumo S; Takashima H J Neurol Sci; 2016 Dec; 371():112-116. PubMed ID: 27871430 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy. Sato T; Yamauchi J; Yagishita N; Araya N; Takao N; Ohta Y; Inoue E; Takahashi M; Yamagishi M; Suzuki Y; Uchimaru K; Matsumoto N; Hasegawa Y; Yamano Y Brain; 2023 Aug; 146(8):3181-3191. PubMed ID: 37093965 [TBL] [Abstract][Full Text] [Related]